Subarachnoid Hemorrhage - Pipeline Review, Q2 2011

Global Markets Direct, May 2011, Pages: 38

Subarachnoid Hemorrhage - Pipeline Review, Q2 2011

Summary

Global Markets Direct’s, 'Subarachnoid Hemorrhage - Pipeline Review, Q2 2011', provides an overview of the Subarachnoid Hemorrhage therapeutic pipeline. This report provides information on the therapeutic development for Subarachnoid Hemorrhage, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Subarachnoid Hemorrhage. 'Subarachnoid Hemorrhage - Pipeline Review, Q2 2011' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note-: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Subarachnoid Hemorrhage.
- A review of the Subarachnoid Hemorrhage products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Subarachnoid Hemorrhage pipeline on the basis of therapeutic class, route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Subarachnoid Hemorrhage.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Subarachnoid Hemorrhage pipeline depth and focus of Subarachnoid Hemorrhage therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Subarachnoid Hemorrhage Overview
Therapeutics Development
An Overview of Pipeline Products for Subarachnoid Hemorrhage
Subarachnoid Hemorrhage Therapeutics under Development by Companies
Subarachnoid Hemorrhage Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Pre-Clinical Stage Products
Comparative Analysis
Subarachnoid Hemorrhage Therapeutics - Products under Development by Companies
Subarachnoid Hemorrhage Therapeutics - Products under Investigation by Universities/Institutes
Companies Involved in Subarachnoid Hemorrhage Therapeutics Development
Actelion Ltd
Subarachnoid Hemorrhage - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
Pivlaz - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Dantrolene - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Simvastatin for Aneurysmal Subarachnoid Haemorrhage (Chinese University of Hong Kong) - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Tissue Plasminogen Activator - Drug Profile
Product Description
Mechanism of Action
R&D Progress
NimoGel - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Erythropoietin Beta - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Magnesium Sulfate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Sildenafil Citrate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Simvastatin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Thiola - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Subarachnoid Hemorrhage Therapeutics – Drug Profile Updates
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products Under Development for Subarachnoid Hemorrhage, Q2 2011
Products under Development for Subarachnoid Hemorrhage – Comparative Analysis, Q2 2011
Number of Products under Development by Companies, Q2 2011
Number of Products under Investigation by Universities/Institutes, Q2 2011
Comparative Analysis by Late Stage Development, Q2 2011
Comparative Analysis by Mid Clinical Stage Development, Q2 2011
Comparative Analysis by Pre-Clinical Stage Development, Q2 2011
Products under Development by Companies, Q2 2011
Products under Investigation by Universities/Institutes, Q2 2011
Actelion Ltd, 2011
Assessment by Monotherapy Products, Q2 2011
Assessment by Stage and Route of Administration, Q2 2011
Assessment by Molecule Type, Q2 2011
Subarachnoid Hemorrhage Therapeutics – Drug Profile Updates

List of Figures
Number of Products under Development for Subarachnoid Hemorrhage, Q2 2011
Products under Development for Subarachnoid Hemorrhage – Comparative Analysis, Q2 2011
Products under Development by Companies, Q2 2011
Products under Investigation by Universities/Institutes, Q2 2011
Late Stage Products, Q2 2011
Mid Clinical Stage Products, Q2 2011
Pre-Clinical Stage Products, Q2 2011
Assessment by Monotherapy Products, Q2 2011
Assessment by Route of Administration, Q2 2011
Assessment by Stage and Route of Administration, Q2 2011
Assessment by Molecule Type, Q2 2011
Assessment by Stage and Molecule Type, Q2 2011

Customers who bought this item also bought

• Aneurysmal Subarachnoid Hemorrhage (SAH) - Pipeline Review, Q4 2010
• Hemorrhage - Pipeline Review, H2 2012
• Hemorrhage - Pipeline Review, H1 2012
• Brain Hemorrhage - Pipeline Review, Q4 2010
• Gastrointestinal Hemorrhage Global Clinical Trials Review, Q2, 2011
• Gastrointestinal Hemorrhage Global Clinical Trials Review, H1, 2013
• Gastrointestinal Hemorrhage Global Clinical Trials Review, H1, 2012
• Transdermal Drug Delivery - Technologies, Markets, and Companies
• Fatty Liver Disease - Pipeline Review, H2 2012
• Nausea - Pipeline Review, H2 2012